All Stories

  1. Prognostic value of liver stiffness measurement vs. biochemical response in primary biliary cholangitis

    Article • Journal of Hepatology, October 2025, Elsevier

    Professor Albert Pares

  2. Bone fractures in primary biliary cholangitis

    Article • Journal of Internal Medicine, May 2023, Wiley

    Professor Albert Pares

  3. Liver stiffness measurement by vibration-controlled transient elastography improves outcome prediction in primary biliary cholangitis

    Article • Journal of Hepatology, December 2022, Elsevier

    Professor Albert Pares

  4. Geographical region and clinical outcomes of patients with primary biliary cholangitis from Western Europe

    Article • European Journal of Gastroenterology & Hepatology, November 2022, Wolters Kluwer Health

    Professor Albert Pares

  5. Liver transplant‐free survival according to alkaline phosphatase and GLOBE score in patients with primary biliary cholangitis treated with ursodeoxycholic acid

    Article • Alimentary Pharmacology & Therapeutics, September 2022, Wiley

    Professor Albert Pares

  6. Artificial liver support in patients with liver failure: a modified DELPHI consensus of international experts

    Article • Intensive Care Medicine, September 2022, Springer Science + Business Media

    Professor Albert Pares

  7. Risk factors and outcomes associated with recurrent autoimmune hepatitis following liver transplantation

    Article • Journal of Hepatology, July 2022, Elsevier

    Professor Albert Pares

  8. Noninvasive Prediction of Outcomes in Autoimmune Hepatitis–Related Cirrhosis

    Article • Hepatology Communications, January 2022, Wolters Kluwer Health

    Professor Albert Pares

  9. Measurement of Gamma Glutamyl Transferase to Determine Risk of Liver Transplantation or Death in Patients With Primary Biliary Cholangitis

    Article • Clinical Gastroenterology and Hepatology, August 2021, Elsevier

    Xavier Verhelst, Professor Albert Pares

  10. Obeticholic Acid and Fibrates in Primary Biliary Cholangitis: Comparative Effects in a Multicentric Observational Study

    Article • The American Journal of Gastroenterology, June 2021, Wolters Kluwer Health

    Professor Albert Pares

  11. A Comparison of Prognostic Scores (Mayo, UK-PBC, and GLOBE) in Primary Biliary Cholangitis

    Article • The American Journal of Gastroenterology, May 2021, Wolters Kluwer Health

    Xavier Verhelst, Professor Albert Pares

  12. Clustering Reveals the Prognostic Role of Serum Albumin Values Within the Normal Range in Patients with Primary Biliary Cholangitis

    Article • Digestive and Liver Disease, March 2021, Elsevier

    Professor Albert Pares

  13. A placebo-controlled randomised trial of budesonide for PBC following an insufficient response to UDCA

    Article • Journal of Hepatology, February 2021, Elsevier

    Professor Albert Pares

  14. Obeticholic acid is associated with improvements in AST-to-platelet ratio index and GLOBE score in patients with primary biliary cholangitis

    Article • JHEP Reports, February 2021, Elsevier

    Professor Albert Pares

  15. Practical management of primary biliary cholangitis

    Article • Revista Española de Enfermedades Digestivas, January 2021, Sociedad Espanola de Patologia Digestiva (SEPD)

    Professor Albert Pares

  16. Simplified care-pathway selection for nonspecialist practice: the GLOBAL Primary Biliary Cholangitis Study Group Age, Bilirubin, Alkaline phosphatase risk assessment tool

    Article • European Journal of Gastroenterology & Hepatology, December 2020, Wolters Kluwer Health

    Xavier Verhelst, Professor Albert Pares

  17. Response to Granito et al.

    Article • The American Journal of Gastroenterology, October 2020, Wolters Kluwer Health

    Professor Albert Pares

  18. Bilirubin and bile acids in osteocytes and bone tissue. Potential role in the cholestatic‐induced osteoporosis

    Article • Liver International, October 2020, Wiley

    Professor Albert Pares

  19. Long-term impact of preventive UDCA therapy after transplantation for primary biliary cholangitis

    Article • Journal of Hepatology, September 2020, Elsevier

    Xavier Verhelst, Professor Albert Pares

  20. Novel Anti–Hexokinase 1 Antibodies Are Associated With Poor Prognosis in Patients With Primary Biliary Cholangitis

    Article • The American Journal of Gastroenterology, May 2020, Wolters Kluwer Health

    Professor Albert Pares

  21. Long-Term Obeticholic Acid Therapy Improves Histological Endpoints in Patients With Primary Biliary Cholangitis

    Article • Clinical Gastroenterology and Hepatology, May 2020, Elsevier

    Professor Albert Pares

  22. Reduction and stabilization of bilirubin with obeticholic acid treatment in patients with primary biliary cholangitis

    Article • Liver International, March 2020, Wiley

    Professor Albert Pares

  23. Factors Associated With Progression and Outcomes of Early Stage Primary Biliary Cholangitis

    Article • Clinical Gastroenterology and Hepatology, March 2020, Elsevier

    Xavier Verhelst, Professor Albert Pares

  24. Goals of Treatment for Improved Survival in Primary Biliary Cholangitis: Treatment Target Should Be Bilirubin Within the Normal Range and Normalization of Alkaline Phosphatase

    Article • The American Journal of Gastroenterology, February 2020, Wolters Kluwer Health

    Xavier Verhelst, Professor Albert Pares

  25. Serum gamma-glutamyltransferase is a prognostic biomarker in primary biliary cholangitis and improves risk stratification based on alkaline phosphatase

    Article • Digestive and Liver Disease, February 2020, Elsevier

    Professor Albert Pares

  26. Higher seroprevalence of hepatitis E virus in autoimmune hepatitis: Role of false‐positive antibodies

    Article • Liver International, January 2020, Wiley

    Professor Albert Pares

  27. Bile acids and bilirubin effects on osteoblastic gene profile. Implications in the pathogenesis of osteoporosis in liver diseases

    Article • Gene, January 2020, Elsevier

    Professor Albert Pares

  28. Number needed to treat with ursodeoxycholic acid therapy to prevent liver transplantation or death in primary biliary cholangitis

    Article • Gut, December 2019, BMJ

    Professor Albert Pares

  29. Presentation and Outcomes of Pregnancy in Patients With Autoimmune Hepatitis

    Article • Clinical Gastroenterology and Hepatology, December 2019, Elsevier

    Professor Albert Pares

  30. Fibrosis stage is an independent predictor of outcome in primary biliary cholangitis despite biochemical treatment response

    Article • Alimentary Pharmacology & Therapeutics, October 2019, Wiley

    Xavier Verhelst, Professor Albert Pares

  31. Effects of Age and Sex of Response to Ursodeoxycholic Acid and Transplant-free Survival in Patients With Primary Biliary Cholangitis

    Article • Clinical Gastroenterology and Hepatology, September 2019, Elsevier

    Xavier Verhelst, Professor Albert Pares

  32. Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis

    Article • Journal of Hepatology, August 2019, Elsevier

    Professor Albert Pares

  33. ATU-09 Obeticholic acid treatment is associated with improved collagen morphometry in patients with primary biliary cholangitis

    Article • June 2019, BMJ

    Professor Albert Pares

  34. Suppression of a broad spectrum of liver autoimmune pathologies by single peptide-MHC-based nanomedicines

    Article • Nature Communications, May 2019, Springer Science + Business Media

    Professor Albert Pares

  35. The Prevalence of Anti-Hexokinase-1 and Anti-Kelch-Like 12 Peptide Antibodies in Patients With Primary Biliary Cholangitis Is Similar in Europe and North America: A Large International, Multi-Center Study

    Article • Frontiers in Immunology, April 2019, Frontiers

    Professor Albert Pares

  36. FRI-021-Comparing the predictive performance of the Mayo risk score and the GLOBE score in a large cohort of patients with primary biliary cholangitis

    Article • Journal of Hepatology, April 2019, Elsevier

    Professor Albert Pares

  37. FRI-033-Long-term obeticholic acid treatment is associated with improvements in collagen morphometry in patients with primary biliary cholangitis

    Article • Journal of Hepatology, April 2019, Elsevier

    Professor Albert Pares

  38. GS-18-Preventive administration of ursodeoxycholic acid after liver transplantation for primary biliary cholangitis prevents disease recurrence and prolongs graft survival

    Article • Journal of Hepatology, April 2019, Elsevier

    Professor Albert Pares

  39. FRI-046-Raising awareness and messaging risk in patients with primary biliary cholangitis: The rapid Global PBC Screening Test

    Article • Journal of Hepatology, April 2019, Elsevier

    Professor Albert Pares

  40. Three years of obeticholic Acid (OCA) therapy results in histological improvements in patients with primary biliary cholangitis: further analysis of the POISE Biopsy substudy

    Article • Digestive and Liver Disease, February 2019, Elsevier

    Professor Albert Pares

  41. EASL Clinical Practice Guidelines on nutrition in chronic liver disease

    Article • Journal of Hepatology, January 2019, Elsevier

    Professor Albert Pares

  42. Factors Associated With Recurrence of Primary Biliary Cholangitis After Liver Transplantation and Effects on Graft and Patient Survival

    Article • Gastroenterology, January 2019, Elsevier

    Professor Albert Pares, Xavier Verhelst

  43. Primary sclerosing cholangitis response to the combination of fibrates with ursodeoxycholic acid: French–Spanish experience

    Article • Clinics and Research in Hepatology and Gastroenterology, December 2018, Elsevier

    Professor Albert Pares

  44. Colangitis biliar primaria

    Article • Medicina Clínica, September 2018, Elsevier

    Professor Albert Pares

  45. Primary biliary cholangitis and bone disease

    Article • Best Practice & Research Clinical Gastroenterology, June 2018, Elsevier

    Professor Albert Pares

  46. Milder disease stage in patients with primary biliary cholangitis over a 44-year period: A changing natural history

    Article • Hepatology, April 2018, Wiley

    Xavier Verhelst, Professor Albert Pares

  47. A dose-response relationship in the association between ursodeoxycholic acid treatment and prolonged transplant-free survival in primary biliary cholangitis

    Article • Journal of Hepatology, April 2018, Elsevier

    Professor Albert Pares

  48. Change in bilirubin with obeticholic acid treatment in primary biliary cholangitis patients with high baseline bilirubin: a retrospective analysis of POISE, 201, and 202

    Article • Journal of Hepatology, April 2018, Elsevier

    Professor Albert Pares

  49. Histologic stage is a stronger predictor of transplant free survival than APRI and FIB-4 in patients with primary biliary cholangitis

    Article • Journal of Hepatology, April 2018, Elsevier

    Professor Albert Pares

  50. Long-Term Obeticholic Acid (OCA) treatment associated with reversal or stabilization of fibrosis/cirrhosis in patients with Primary Biliary Cholangitis (PBC)

    Article • Journal of Hepatology, April 2018, Elsevier

    Professor Albert Pares

  51. Pregnancy and autoimmune hepatitis: presentation and outcomes

    Article • Journal of Hepatology, April 2018, Elsevier

    Professor Albert Pares

  52. Primary biliary cholangitis in Spain: fewer symptoms and milder disease at presentation, but similar therapeutic response over the years

    Article • Journal of Hepatology, April 2018, Elsevier

    Professor Albert Pares

  53. Results of a randomised controlled trial of budesonide add-on therapy in patients with primary biliary cholangitis and an incomplete response to ursodeoxycholic acid

    Article • Journal of Hepatology, April 2018, Elsevier

    Professor Albert Pares

  54. Stratification of hepatocellular carcinoma risk using the GLOBE score in patients with primary biliary cholangitis– the Global PBC Study Group

    Article • Journal of Hepatology, April 2018, Elsevier

    Professor Albert Pares

  55. Ursodeoxycholic acid treatment is associated with prolonged transplant-free survival in primary biliary cholangitis – even in patients without biochemical improvements

    Article • Journal of Hepatology, April 2018, Elsevier

    Professor Albert Pares

  56. Younger age is associated with lower transplant-free survival relative to a general population in patients with Primary Biliary Cholangitis

    Article • Journal of Hepatology, April 2018, Elsevier

    Professor Albert Pares

  57. Osteoporosis in chronic liver disease

    Article • Liver International, March 2018, Wiley

    Professor Albert Pares

  58. A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis

    Article • Hepatology, January 2018, Wiley

    Roger Chapman, Professor Albert Pares

  59. Primary biliary cholangitis in Spain. Results of a Delphi study of epidemiology, diagnosis, follow-up and treatment

    Article • Revista Española de Enfermedades Digestivas, January 2018, Sociedad Espanola de Patologia Digestiva (SEPD)

    Professor Albert Pares

  60. Major Hepatic Complications in Ursodeoxycholic Acid-Treated Patients With Primary Biliary Cholangitis: Risk Factors and Time Trends in Incidence and Outcome

    Article • The American Journal of Gastroenterology, December 2017, Wolters Kluwer Health

    Professor Albert Pares, Xavier Verhelst

  61. Efficacy and Safety of Mycophenolate Mofetil and Tacrolimus as Second-line Therapy for Patients With Autoimmune Hepatitis

    Article • Clinical Gastroenterology and Hepatology, December 2017, Elsevier

    Professor Albert Pares

  62. Advances in treatment options for patients with primary biliary cholangitis

    Article • Expert Opinion on Orphan Drugs, October 2017, Taylor & Francis

    Professor Albert Pares

  63. Effects of Bezafibrate on Outcome and Pruritus in Primary Biliary Cholangitis With Suboptimal Ursodeoxycholic Acid Response

    Article • The American Journal of Gastroenterology, October 2017, Wolters Kluwer Health

    Professor Albert Pares

  64. Effect of Obeticholic Acid Treatment in Patients With Primary Biliary Cholangitis on Categorical Shifts in GLOBE Score

    Article • The American Journal of Gastroenterology, October 2017, Wolters Kluwer Health

    Professor Albert Pares

  65. Genetic association analysis identifies variants associated with disease progression in primary sclerosing cholangitis

    Article • Gut, August 2017, BMJ

    Professor Albert Pares, Prof. Dr. Bart van Hoek

  66. Patient Age, Sex, and Inflammatory Bowel Disease Phenotype Associate With Course of Primary Sclerosing Cholangitis

    Article • Gastroenterology, June 2017, Elsevier

    Professor Albert Pares

  67. Fibrates for the treatment of cholestatic itch (FITCH): study protocol for a randomized controlled trial

    Article • Trials, May 2017, Springer Science + Business Media

    Professor Albert Pares, Prof. Dr. Bart van Hoek

  68. Enhanced liver fibrosis test predicts transplant-free survival in primary sclerosing cholangitis, a multi-centre study

    Article • Liver International, April 2017, Wiley

    Professor Albert Pares

  69. Juan Rodés. A successful and extraordinary life of a visionary hepatologist

    Article • Gut, March 2017, BMJ

    Professor Albert Pares

  70. An appealing new agent for treating cholestatic pruritus

    Article • The Lancet, March 2017, Elsevier

    Professor Albert Pares

  71. Novel Treatment Strategies for Primary Biliary Cholangitis

    Article • Seminars in Liver Disease, February 2017, Thieme Publishing Group

    Professor Albert Pares

  72. Expert clinical management of autoimmune hepatitis in the real world

    Article • Alimentary Pharmacology & Therapeutics, December 2016, Wiley

    Professor Albert Pares, Prof. Dr. Bart van Hoek

  73. Genome-wide association study of primary sclerosing cholangitis identifies new risk loci and quantifies the genetic relationship with inflammatory bowel disease

    Article • Nature Genetics, December 2016, Nature

    Professor Albert Pares

  74. Thyroid Dysfunction in Primary Biliary Cholangitis: A Comparative Study at Two European Centers

    Article • The American Journal of Gastroenterology, October 2016, Nature

    Professor Albert Pares

  75. Colangitis biliar primaria

    Article • Medicine - Programa de Formación Médica Continuada Acreditado, May 2016, Elsevier

    Professor Albert Pares

  76. Sclerostin Expression in Bile Ducts of Patients With Chronic Cholestasis May Influence the Bone Disease in Primary Biliary Cirrhosis

    Article • Journal of Bone and Mineral Research, April 2016, Wiley

    Professor Albert Pares

  77. Enteroendocrine cells are a potential source of serum autotaxin in men

    Article • Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, April 2016, Elsevier

    Professor Albert Pares

  78. Preface

    Article • Digestive Diseases, December 2015, Karger Publishers

    Professor Albert Pares

  79. Therapy of Primary Biliary Cirrhosis: Novel Approaches for Patients with Suboptimal Response to Ursodeoxycholic Acid

    Article • Digestive Diseases, December 2015, Karger Publishers

    Professor Albert Pares

  80. Development and Validation of a Scoring System to Predict Outcomes of Patients With Primary Biliary Cirrhosis Receiving Ursodeoxycholic Acid Therapy

    Article • Gastroenterology, December 2015, Elsevier

    Professor Albert Pares

  81. Risk stratification in autoimmune cholestatic liver diseases: Opportunities for clinicians and trialists

    Article • Hepatology, November 2015, Wiley

    Professor Albert Pares

  82. Changing nomenclature for PBC: From ‘cirrhosis’ to ‘cholangitis’

    Article • Journal of Hepatology, November 2015, Elsevier

    Professor Albert Pares

  83. Changing Nomenclature for PBC: From ‘Cirrhosis’ to ‘Cholangitis’

    Article • Clinical Gastroenterology and Hepatology, November 2015, Elsevier

    Professor Albert Pares

  84. Changing Nomenclature for PBC: From ‘Cirrhosis’ to ‘Cholangitis’

    Article • Gastroenterology, November 2015, Elsevier

    Professor Albert Pares

  85. Changing nomenclature for PBC: From ‘cirrhosis’ to ‘cholangitis’

    Article • Digestive and Liver Disease, November 2015, Elsevier

    Professor Albert Pares

  86. Changing nomenclature for PBC: From ‘cirrhosis’ to ‘cholangitis’

    Article • Clinics and Research in Hepatology and Gastroenterology, October 2015, Elsevier

    Professor Albert Pares

  87. Changing Nomenclature for PBC: From ‘Cirrhosis’ to ‘Cholangitis’

    Article • The American Journal of Gastroenterology, September 2015, Nature

    Professor Albert Pares

  88. Changing nomenclature for PBC: From ‘cirrhosis’ to ‘cholangitis’

    Article • Hepatology, September 2015, Wiley

    Professor Albert Pares

  89. Changing nomenclature for PBC: from ‘cirrhosis’ to ‘cholangitis’

    Article • Gut, September 2015, BMJ

    Professor Albert Pares

  90. Histone deacetylase 4 promotes cholestatic liver injury in the absence of prohibitin-1

    Article • Hepatology, July 2015, Wiley

    Professor Albert Pares

  91. Enhanced liver fibrosis score predicts transplant-free survival in primary sclerosing cholangitis

    Article • Hepatology, April 2015, Wiley

    Professor Albert Pares

  92. Efficacy of Obeticholic Acid in Patients With Primary Biliary Cirrhosis and Inadequate Response to Ursodeoxycholic Acid

    Article • Gastroenterology, April 2015, Elsevier

    Professor Albert Pares

  93. Stratification of hepatocellular carcinoma risk in primary biliary cirrhosis: a multicentre international study

    Article • Gut, January 2015, BMJ

    Professor Albert Pares

  94. Bone Disease in Patients with Cirrhosis

    Article • January 2015, Springer Science + Business Media

    Professor Albert Pares

  95. TRAIL-producing NK cells contribute to liver injury and related fibrogenesis in the context of GNMT deficiency

    Article • Laboratory Investigation, December 2014, Nature

    Professor Albert Pares

  96. Levels of Alkaline Phosphatase and Bilirubin Are Surrogate End Points of Outcomes of Patients With Primary Biliary Cirrhosis: An International Follow-up Study

    Article • Gastroenterology, December 2014, Elsevier

    Professor Albert Pares

  97. Ursodeoxycholic acid decreases bilirubin-induced osteoblast apoptosis

    Article • European Journal of Clinical Investigation, November 2014, Wiley

    Professor Albert Pares

  98. Poster Session 1: Cholestasis and Autoimmune Liver Disease

    Article • Hepatology, October 2014, Wolters Kluwer Health

    Professor Albert Pares

  99. Extrahepatic Malignancies in Primary Biliary Cirrhosis: A Comparative Study at Two European Centers

    Article • Clinical Reviews in Allergy & Immunology, September 2014, Springer Science + Business Media

    Professor Albert Pares

  100. Old and Novel Therapies for Primary Biliary Cirrhosis

    Article • Seminars in Liver Disease, July 2014, Thieme Publishing Group

    Professor Albert Pares

  101. Treatment of primary biliary cirrhosis: Is there more to offer than ursodeoxycholic acid?

    Article • Clinical Liver Disease, February 2014, Wolters Kluwer Health

    Professor Albert Pares

  102. Extracorporeal liver support in severe alcoholic hepatitis

    Article • World Journal of Gastroenterology, January 2014, Baishideng Publishing Group Co., Limited (formerly WJG Press)

    Professor Albert Pares

  103. Randomized trial comparing monthly ibandronate and weekly alendronate for osteoporosis in patients with primary biliary cirrhosis

    Article • Hepatology, October 2013, Wolters Kluwer Health

    Professor Albert Pares

  104. Bezafibrate normalizes alkaline phosphatase in primary biliary cirrhosis patients with incomplete response to ursodeoxycholic acid

    Article • Liver International, September 2013, Wiley

    Professor Albert Pares

  105. Ursodeoxycholic acid protects osteoblastic cells from bilirubin and lithocholic acid induced apoptosis

    Article • May 2013

    Professor Albert Pares

  106. Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis

    Article • Nature Genetics, April 2013, Springer Science + Business Media

    Professor Albert Pares, Dr Tobias J. Weismüller

  107. Ursodeoxycholic acid increases differentiation and mineralization and neutralizes the damaging effects of bilirubin on osteoblastic cells

    Article • Liver International, April 2013, Wiley

    Professor Albert Pares

  108. 950 PROGNOSIS OF PRIMARY BILIARY CIRRHOSIS WITH FEATURES OF AUTOIMMUNE HEPATITIS OVERLAP SYNDROME. ROLE OF URSODEOXYCHOLIC ACID IN LONG-TERM SURVIVAL

    Article • Journal of Hepatology, April 2013, Elsevier

    Professor Albert Pares

  109. 941 ALKALINE PHOSPHATASE VALUES ARE A SURROGATE MARKER IN PREDICTION OF TRANSPLANT FREE SURVIVAL IN PATIENTS WITH PRIMARY BILIARY CIRRHOSIS – AN INTERNATIONAL, COLLABORATIVE ANALYSIS

    Article • Journal of Hepatology, April 2013, Elsevier

    Professor Albert Pares

  110. 930 DECREASE OF LIVER STIFFNESS IN PATIENTS WITH PRIMARY BILIARY CIRRHOSIS AND BIOCHEMICAL RESPONSE TO URSODEOXYCHOLIC ACID

    Article • Journal of Hepatology, April 2013, Elsevier

    Professor Albert Pares

  111. Extracorporeal albumin dialysis with the molecular adsorbent recirculating system in acute-on-chronic liver failure: The RELIEF trial

    Article • Hepatology, March 2013, Wolters Kluwer Health

    Professor Albert Pares

  112. Hepatotoxicity associated with glucosamine and chondroitin sulfate in patients with chronic liver disease

    Article • World Journal of Gastroenterology, January 2013, Baishideng Publishing Group Co., Limited (formerly WJG Press)

    Professor Albert Pares

  113. Soil Organic Carbon is Increased in Mixed-Species Plantations of Eucalyptus and Nitrogen-Fixing Acacia

    Article • Ecosystems, September 2012, Springer Science + Business Media

    Professor Albert Pares

  114. Osteoporosis en la cirrosis hepática

    Article • Gastroenterología y Hepatología, June 2012, Elsevier

    Professor Albert Pares

  115. 38 SERUM METABOLOMIC PROFILING IN PATIENTS WITH CHOLESTATIC PRURITUS

    Article • Journal of Hepatology, April 2012, Elsevier

    Professor Albert Pares

  116. 970 SERUM AUTOTAXIN ACTIVITY IS ASSOCIATED WITH PRURITUS AND DISEASE DURATION AND SEVERITY IN PRIMARY BILIARY CIRRHOSIS

    Article • Journal of Hepatology, April 2012, Elsevier

    Professor Albert Pares

  117. 952 LONG-TERM (LT) THERAPY OF A FARNESOID X RECEPTOR (FXR) AGONIST OBETICHOLIC ACID (OCA) MAINTAINS BIOCHEMICAL RESPONSE IN PRIMARY BILIARY CIRRHOSIS (PBC)

    Article • Journal of Hepatology, April 2012, Elsevier

    Professor Albert Pares

  118. 964 THE FARNESOID X RECEPTOR (FXR) AGONIST OBETICHOLIC ACID (OCA) INCREASES PLASMA FGF-19 CONCENTRATIONS AND DECREASES BILE ACID SYNTHESIS IN PRIMARY BILIARY CIRRHOSIS (PBC)

    Article • Journal of Hepatology, April 2012, Elsevier

    Professor Albert Pares

  119. Sex Differences Associated with Primary Biliary Cirrhosis

    Article • Clinical and Developmental Immunology, January 2012, Hindawi Publishing Corporation

    Professor Albert Pares, Professor DIMITRIOS P BOGDANOS

  120. Tuberculosis Is Not a Risk Factor for Primary Biliary Cirrhosis: A Review of the Literature

    Article • Tuberculosis Research and Treatment, January 2012, Hindawi Publishing Corporation

    Professor Albert Pares

  121. Role for mycobacterial infection in pathogenesis of primary biliary cirrhosis?

    Article • World Journal of Gastroenterology, January 2012, Baishideng Publishing Group Co., Limited (formerly WJG Press)

    Professor Albert Pares, Professor DIMITRIOS P BOGDANOS

  122. Hepatitis aguda alcohólica

    Article • Revista Española de Enfermedades Digestivas, November 2011, Instituto de Salud Carlos III/BNCS/SciELO Espana

    Professor Albert Pares

  123. Fibratos en el tratamiento de la cirrosis biliar primaria

    Article • Gastroenterología y Hepatología Continuada, November 2011, Elsevier

    Professor Albert Pares

  124. Colangiopatía IgG4. Características clínicas y diagnóstico diferencial

    Article • Gastroenterología y Hepatología Continuada, September 2011, Elsevier

    Professor Albert Pares

  125. OP02 The first new monotherapy therapeutic PBC study in a decade? An international study evaluating the farnesoid X receptor agonist obeticholic acid in PBC: Abstract OP02 Table 1

    Article • Gut, September 2011, BMJ

    Professor Albert Pares

  126. Patients with cirrhosis and ascites have false values of bone density

    Article • Osteoporosis International, August 2011, Springer Science + Business Media

    Professor Albert Pares

  127. Proteomic Analysis of Polypeptides Captured from Blood during Extracorporeal Albumin Dialysis in Patients with Cholestasis and Resistant Pruritus

    Article • PLOS One, July 2011, PLOS

    Professor Albert Pares

  128. Management of osteoporosis in liver disease

    Article • Clinics and Research in Hepatology and Gastroenterology, June 2011, Elsevier

    Professor Albert Pares

  129. Ursodeoxycholic acid neutralizes the noxious effects of lithocholic acid and bilirubin on osteoblasts

    Article • Bone, May 2011, Elsevier

    Professor Albert Pares

  130. 1306 URSODEOXYCHOLIC ACID NEUTRALIZES THE NOXIOUS EFFECTS OF LITHOCHOLIC ACID AND BILIRUBIN ON OSTEOBLASTS

    Article • Journal of Hepatology, March 2011, Elsevier

    Professor Albert Pares

  131. 28 AN INTERNATIONAL STUDY EVALUATING THE FARNESOID X RECEPTOR AGONIST OBETICHOLIC ACID AS MONOTHERAPY IN PBC

    Article • Journal of Hepatology, March 2011, Elsevier

    Professor Albert Pares

  132. 1299 PROMISING EFFECTS OF BEZAFIBRATE IN PATIENTS WITH PRIMARY BILIARY CIRRHOSIS AND INCOMPLETE RESPONSE TO URSODEOXYCHOLIC ACID

    Article • Journal of Hepatology, March 2011, Elsevier

    Professor Albert Pares

  133. Colangitis esclerosante primaria: diagnóstico, pronóstico y tratamiento

    Article • Gastroenterología y Hepatología, January 2011, Elsevier

    Professor Albert Pares

  134. Enfermedad de Caroli

    Article • Gastroenterología y Hepatología Continuada, January 2011, Elsevier

    Professor Albert Pares

  135. Reply

    Article • Hepatology, December 2010, Wolters Kluwer Health

    Professor Albert Pares

  136. Print and Media Review

    Article • Gastroenterology, December 2010, Elsevier

    Professor Albert Pares

  137. Effects of bilirubin and sera from jaundiced patients on osteoblasts: Contribution to the development of osteoporosis in liver diseases

    Article • Hepatology, December 2010, Wolters Kluwer Health

    Professor Albert Pares

  138. Liver and bone

    Article • Archives of Biochemistry and Biophysics, November 2010, Elsevier

    Professor Albert Pares

  139. Characterization of peptides and proteins in commercial HSA solutions

    Article • PROTEOMICS - CLINICAL APPLICATIONS, September 2010, Wiley

    Professor Albert Pares

  140. Treatment of resistant pruritus from cholestasis with albumin dialysis: Combined analysis of patients from three centers

    Article • Journal of Hepatology, August 2010, Elsevier

    Professor Albert Pares

  141. Low Bone Mass and Severity of Cholestasis Affect Fracture Risk in Patients With Primary Biliary Cirrhosis

    Article • Gastroenterology, June 2010, Elsevier

    Professor Albert Pares

  142. Psicosis y diferencias sociales: Comparando la prevalencia de las psicosis en dos medios urbanos diferenciados

    Article • Revista de la Asociación Española de Neuropsiquiatría, June 2010, Instituto de Salud Carlos III/BNCS/SciELO Espana

    Professor Albert Pares

  143. 184 MONTHLY IBANDRONATE VS. WEEKLY ALENDRONATE IN THE TREATMENT OF OSTEOPOROSIS ASSOCIATED WITH PRIMARY BILIARY CIRRHOSIS: SIMILAR EFFICACY BUT DIFFERENT ADHERENCE

    Article • Journal of Hepatology, April 2010, Elsevier

    Professor Albert Pares

  144. 535 HIGH BILIRUBIN REDUCES CELL SURVIVAL AND DIFFERENTIATION OF PRIMARY HUMAN OSTEOBLASTS. IS THIS EFFECT APPLICABLE TO THE SERUM OF CHRONIC CHOLESTATIC PATIENTS?

    Article • Journal of Hepatology, April 2010, Elsevier

    Professor Albert Pares

  145. 849 PATIENTS WITH ASCITES HAVE FALSE VALUES OF BONE MINERAL DENSITY AT THE CENTRAL SKELETON. A PROSPECTIVE STUDY

    Article • Journal of Hepatology, April 2010, Elsevier

    Professor Albert Pares

  146. 2 FARNESOID-X RECEPTOR AGONISTS: A NEW CLASS OF DRUGS FOR THE TREATMENT OF PBC? AN INTERNATIONAL STUDY EVALUATING THE ADDITION OF INT-747 TO URSODEOXYCHOLIC ACID

    Article • Journal of Hepatology, April 2010, Elsevier

    Professor Albert Pares

  147. Usability Evaluation of the Interactive Personal Patient Profile-Prostate Decision Support System With African American Men

    Article • Journal of the National Medical Association, April 2010, Elsevier

    Professor Albert Pares

  148. The effect of the alendronate on OPG/RANKL system in differentiated primary human osteoblasts

    Article • Endocrine, January 2010, Springer Science + Business Media

    Professor Albert Pares

  149. Characterization of peptides and proteins in commercial HSA solutions

    Article • PROTEOMICS, January 2010, Wiley

    Professor Albert Pares

  150. Lithocholic acid downregulates vitamin D effects in human osteoblasts

    Article • European Journal of Clinical Investigation, January 2010, Wiley

    Professor Albert Pares

  151. The effect of the alendronate on OPG/RANKL system in differentiated primary human osteoblasts

    Article • Endocrine, November 2009, Springer Science + Business Media

    Professor Albert Pares

  152. Incidence, Risk Factors, and Survival of Hepatocellular Carcinoma in Primary Biliary Cirrhosis

    Article • Hepatology, October 2009, Wolters Kluwer Health

    Professor Albert Pares

  153. Utilidad del ácido ursodeoxicólico en la colangitis esclerosante primaria

    Article • Gastroenterología y Hepatología Continuada, August 2009, Elsevier

    Professor Albert Pares

  154. EASL Clinical Practice Guidelines: Management of cholestatic liver diseases

    Article • Journal of Hepatology, August 2009, Elsevier

    Professor Albert Pares

  155. Neighborhood differences in psychoses: Prevalence of psychotic disorders in two socially-differentiated metropolitan areas of Barcelona

    Article • Schizophrenia Research, July 2009, Elsevier

    Professor Albert Pares

  156. Lithocholic acid decreases cell survival and downregulates the effects of vitamin d3 on primary human osteoblasts

    Article • Bone, June 2009, Elsevier

    Professor Albert Pares

  157. Risk factors for fracture and osteopenia in primary biliary cirrhosis

    Article • Bone, June 2009, Elsevier

    Professor Albert Pares

  158. 106 IDENTIFICATION OF AN EXTREMELY BENIGN ASYMPTOMATIC PRESENTATION IN A LARGE COHORT OF PATIENTS WITH PRIMARY BILIARY CIRRHOSIS

    Article • Journal of Hepatology, April 2009, Elsevier

    Professor Albert Pares

  159. 662 CHARACTERIZATION OF PEPTIDES AND PROTEINS CAPTURED BY THE MARS SYSTEM IN PATIENTS WITH CHOLESTASIS AND RESISTANT PRURITUS

    Article • Journal of Hepatology, April 2009, Elsevier

    Professor Albert Pares

  160. 61 INCIDENCE AND RISK FACTORS FOR HEPATOCELLULAR CARCINOMA IN PRIMARY BILIARY CIRRHOSIS. COMPARATIVE ANALYSIS FROM TWO EUROPEAN REFERRAL CENTERS

    Article • Journal of Hepatology, April 2009, Elsevier

    Professor Albert Pares

  161. New ELISA for Detecting Primary Biliary Cirrhosis-Specific Antimitochondrial Antibodies

    Article • Clinical Chemistry, March 2009, AACC

    Professor Albert Pares, Professor DIMITRIOS P BOGDANOS

  162. High osteoprotegerin serum levels in primary biliary cirrhosis are associated with disease severity but not with the mRNA gene expression in liver tissue

    Article • Journal of Bone and Mineral Metabolism, February 2009, Springer Science + Business Media

    Professor Albert Pares

  163. Albumin dialysis improves hepatic encephalopathy and decreases circulating phenolic aromatic amino acids in patients with alcoholic hepatitis and severe liver failure

    Article • Critical Care, January 2009, Springer Science + Business Media

    Professor Albert Pares

  164. Excellent long-term survival in patients with primary biliary cirrhosis treated with ursodeoxycholic acid

    Article • January 2009, Springer Science + Business Media

    Professor Albert Pares

  165. Historia natural de la cirrosis biliar primaria

    Article • Gastroenterología y Hepatología, October 2008, Elsevier

    Professor Albert Pares

  166. Simplified criteria for the diagnosis of autoimmune hepatitis†

    Article • Hepatology, July 2008, Wolters Kluwer Health

    Professor Albert Pares

  167. Osteoporosis in Primary Biliary Cirrhosis: Pathogenesis and Treatment

    Article • Clinics in Liver Disease, May 2008, Elsevier

    Professor Albert Pares

  168. 874 INCIDENCE AND RISK FACTORS FOR HEPATOCELLULAR CARCINOMA IN PRIMARY BILIARY CIRRHOSIS

    Article • Journal of Hepatology, January 2008, Elsevier

    Professor Albert Pares

  169. 123 PRESENTATION AND NATURAL HISTORY OF PRIMARY BILIARY CIRRHOSIS IN SPAIN: EXPERIENCE OVER 35 YEARS

    Article • Journal of Hepatology, January 2008, Elsevier

    Professor Albert Pares

  170. Primary Sclerosing Cholangitis

    Article • January 2008, Springer Science + Business Media

    Professor Albert Pares

  171. Anti-gp210 antibody mirrors disease severity in primary biliary cirrhosis

    Article • Hepatology, June 2007, Wolters Kluwer Health

    Professor Albert Pares, Professor DIMITRIOS P BOGDANOS

  172. Serum paraoxonase-1 in chronic alcoholics: Relationship with liver disease

    Article • Clinical Biochemistry, June 2007, Elsevier

    Professor Albert Pares

  173. [674] PRESENTATION, COURSE, AND OUTCOME OF A SINGLE-CENTRE COHORT OF PATIENTS WITH PRIMARY BILIARY CIRRHOSIS: CHANGES THROUGH THREE DECADES

    Article • Journal of Hepatology, April 2007, Elsevier

    Professor Albert Pares

  174. Trastornos esquizofrénicos en la atención primaria a la salud mental

    Article • Atención Primaria, March 2007, Elsevier

    Professor Albert Pares

  175. Treatment of bone disorders in liver disease

    Article • Journal of Hepatology, September 2006, Elsevier

    Professor Albert Pares

  176. 641 A study of primary biliary cirrhosis specific antinuclear antibodies in predicting disease severity and outcome

    Article • Journal of Hepatology, April 2006, Elsevier

    Professor Albert Pares

  177. 646 Once-weekly compared with daily alendronate for low bone mass in women with primary biliary cirrhosis

    Article • Journal of Hepatology, April 2006, Elsevier

    Professor Albert Pares

  178. Excellent Long-Term Survival in Patients With Primary Biliary Cirrhosis and Biochemical Response to Ursodeoxycholic Acid

    Article • Gastroenterology, March 2006, Elsevier

    Professor Albert Pares

  179. Simplified Diagnostic Criteria for Autoimmune Hepatitis

    Article • Zeitschrift für Gastroenterologie, January 2006, Thieme Publishing Group

    Professor Albert Pares

  180. Antimitochondrial antibodies in patients with chronic hepatitis C virus infection: description of 18 cases and review of the literature

    Article • Journal of Viral Hepatitis, November 2005, Wiley

    Professor Albert Pares

  181. Prevalence and Mechanisms of Hyperhomocysteinemia in Chronic Alcoholics

    Article • Alcoholism Clinical and Experimental Research, June 2005, Wiley

    Professor Albert Pares

  182. Severity of cholestasis and advanced histological stage but not menopausal status are the major risk factors for osteoporosis in primary biliary cirrhosis

    Article • Journal of Hepatology, April 2005, Elsevier

    Professor Albert Pares

  183. Prevalence and clinical significance of isotype specific antinuclear antibodies in primary biliary cirrhosis

    Article • Gut, April 2005, BMJ

    Professor Albert Pares, Professor DIMITRIOS P BOGDANOS

  184. Gene polymorphisms as predictors of decreased bone mineral density and osteoporosis in primary biliary cirrhosis

    Article • European Journal of Gastroenterology & Hepatology, March 2005, Wolters Kluwer Health

    Professor Albert Pares

  185. Serum Immunological Profile in Patients with Chronic Autoimmune Cholestasis

    Article • The American Journal of Gastroenterology, November 2004, Wolters Kluwer Health

    Professor Albert Pares

  186. Colangitis esclerosante primaria

    Article • Gastroenterología y Hepatología, November 2004, Elsevier

    Professor Albert Pares

  187. La esquizofrenia en atención primaria: el estudio SASPE (señales de alerta y síntomas prodrómicos de la esquizofrenia en atención primaria)

    Article • Atención Primaria, November 2004, Elsevier

    Professor Albert Pares

  188. Tratamiento de las complicaciones óseas

    Article • Gastroenterología y Hepatología, October 2004, Elsevier

    Professor Albert Pares

  189. Extracorporeal Albumin Dialysis: A Procedure for Prolonged Relief of Intractable Pruritus in Patients with Primary Biliary Cirrhosis

    Article • The American Journal of Gastroenterology, June 2004, Wolters Kluwer Health

    Professor Albert Pares

  190. Disease-specific cross-reactivity between mimicking peptides of heat shock protein of mycobacterium gordonae and dominant epitope of E2 subunit of pyruvate dehydrogenase is common in Spanish but not British patients with primary biliary cirrhosis

    Article • Journal of Autoimmunity, June 2004, Elsevier

    Professor Albert Pares, Professor DIMITRIOS P BOGDANOS

  191. Primary Biliary Cirrhosis Specific Antinuclear Antibodies in Patients from Spain

    Article • The American Journal of Gastroenterology, April 2004, Wolters Kluwer Health

    Professor Albert Pares, Professor DIMITRIOS P BOGDANOS

  192. A randomized placebo controlled trial of vitamin E for alcoholic hepatitis

    Article • Journal of Hepatology, January 2004, Elsevier

    Professor Albert Pares

  193. Colangitis esclerosante primaria

    Article • Gastroenterología y Hepatología, January 2004, Elsevier

    Professor Albert Pares

  194. Natural history of primary biliary cirrhosis

    Article • Clinics in Liver Disease, November 2003, Elsevier

    Professor Albert Pares

  195. Alendronate Is More Effective Than Etidronate for Increasing Bone Mass in Osteopenic Patients With Primary Biliary Cirrhosis

    Article • The American Journal of Gastroenterology, October 2003, Wolters Kluwer Health

    Professor Albert Pares

  196. Alendronate is more effective than etidronate for increasing bone mass in osteopenic patients with primary biliary cirrhosis

    Article • The American Journal of Gastroenterology, October 2003, Nature

    Professor Albert Pares

  197. Combined analysis of the effect of treatment with ursodeoxycholic acid on histologic progression in primary biliary cirrhosis

    Article • Journal of Hepatology, July 2003, Elsevier

    Professor Albert Pares

  198. Albumin dialysis decreases aromatic amino acids and improves hepatic encephalopathy in patients with severe liver dysfunction

    Article • Journal of Hepatology, April 2003, Elsevier

    Professor Albert Pares

  199. Blood levels of antioxidant vitamins in alcoholic liver disease. Relationship to liver damage

    Article • Journal of Hepatology, April 2003, Elsevier

    Professor Albert Pares

  200. Improvement in systemic hemodynamics after albumin dialysis is associated with a decrease in vasoactive agents

    Article • Journal of Hepatology, April 2003, Elsevier

    Professor Albert Pares

  201. Expected developments in hepatology

    Article • Best Practice & Research Clinical Gastroenterology, December 2002, Elsevier

    Professor Albert Pares

  202. Cerebral consequences of alcoholic liver disease

    Article • May 2002, Taylor & Francis

    Professor Albert Pares

  203. Hyperhomocysteinemia in chronic alcoholism. Relationship to liver damage

    Article • Journal of Hepatology, April 2002, Elsevier

    Professor Albert Pares

  204. The molecular adsorbent recirculating system (MARS) improves systemic hemodynamics and hepatic encephalopathy in patients with severe alcoholic hepatitis

    Article • Journal of Hepatology, April 2002, Elsevier

    Professor Albert Pares

  205. Molecular adsorbent recirculating system: a new procedure for relieving intractable pruritus in patients with primary biliary cirrhosis

    Article • Journal of Hepatology, April 2002, Elsevier

    Professor Albert Pares

  206. Duration and severity of the disease but not menopausal status are the main risk factors for osteoporosis in primary biliary cirrhosis

    Article • Journal of Hepatology, April 2002, Elsevier

    Professor Albert Pares

  207. Genetic polymorphisms of alcohol metabolizing enzymes do not influence the development of alcoholic liver disease

    Article • Journal of Hepatology, April 2002, Elsevier

    Professor Albert Pares

  208. Time-dependent Cox regression model is superior in prediction of prognosis in primary sclerosing cholangitis

    Article • Hepatology, March 2002, Wiley

    Professor Albert Pares

  209. Cholangiocarcinoma in Primary Sclerosing Cholangitis: Risk Factors and Clinical Presentation

    Article • Scandinavian Journal of Gastroenterology, January 2002, Taylor & Francis

    Professor Albert Pares

  210. Association of the tumour necrosis factor alpha -308 but not the interleukin 10 -627 promoter polymorphism with genetic susceptibility to primary sclerosing cholangitis

    Article • Gut, August 2001, BMJ

    Professor Albert Pares

  211. The HLA-DR3,DQ2 Heterozygous Genotype is Associated with an Accelerated Progression of Primary Sclerosing Cholangitis

    Article • Scandinavian Journal of Gastroenterology, August 2001, Taylor & Francis

    Professor Albert Pares

  212. Hepatocellular Carcinoma in Primary Biliary Cirrhosis: Similar Incidence To That in Hepatitis C Virus–Related Cirrhosis

    Article • The American Journal of Gastroenterology, April 2001, Wolters Kluwer Health

    Professor Albert Pares

  213. Long-term ursodeoxycholic acid treatment delays progression of mild primary biliary cirrhosis

    Article • Journal of Hepatology, April 2001, Elsevier

    Professor Albert Pares

  214. Factors influencing histological progression of early primary biliary cirrhosis. Effect of ursodeoxycholic acid

    Article • Journal of Hepatology, April 2001, Elsevier

    Professor Albert Pares

  215. Hepatocellular carcinoma in primary biliary cirrhosis: similar incidence to that in hepatitis C virus–related cirrhosis

    Article • The American Journal of Gastroenterology, April 2001, Nature

    Professor Albert Pares

  216. Alendronate versus etidronate for osteopenic patients with primary biliary cirrhosis: results after two years of treatment

    Article • Journal of Hepatology, April 2001, Elsevier

    Professor Albert Pares

  217. Cross-reactivity between mycobacterium gordonae and PDC-E2, the major target of anti-mitochondrial antibody, is present in Spanish but not British patients with PBC

    Article • Journal of Hepatology, April 2001, Elsevier

    Professor Albert Pares

  218. Factors influencing histological progression of early primary biliary cirrhosis. Effect of ursodeoxycholic acid

    Article • Journal of Hepatology, April 2001, Elsevier

    Professor Albert Pares

  219. Influence of the genetic polymorphism of collagen type I A2 in the development of alcoholic cirrhosis

    Article • Journal of Hepatology, April 2001, Elsevier

    Professor Albert Pares

  220. Long-term ursodeoxycholic acid treatment delays progression of mild primary biliary cirrhosis

    Article • Journal of Hepatology, April 2001, Elsevier

    Professor Albert Pares

  221. Collagen type Iα1 and vitamin D receptor gene polymorphisms and bone mass in primary biliary cirrhosis

    Article • Hepatology, March 2001, Wiley

    Professor Albert Pares

  222. S-Adenosylmethionine prevents hepatic tocopherol depletion in carbon tetrachloride-injured rats

    Article • Clinical Science, October 2000, Portland Press Ltd.

    Professor Albert Pares

  223. Antibodies against the COOH-terminal region of E. coli ClpP protease in patients with primary biliary cirrhosis

    Article • Journal of Hepatology, October 2000, Wiley

    Professor Albert Pares

  224. Antibodies against the COOH-terminal region of E. coli ClpP protease in patients with primary biliary cirrhosis

    Article • Journal of Hepatology, October 2000, Elsevier

    Professor Albert Pares

  225. Short- and long-term outcome of severe alcohol-induced hepatitis treated with steroids or enteral nutrition: A multicenter randomized trial

    Article • Hepatology, July 2000, Wolters Kluwer Health

    Professor Albert Pares

  226. Enhanced DNA Binding and Activation of Transcription Factors NF-kappa B and AP-1 by Acetaldehyde in HEPG2 Cells

    Article • Journal of Biological Chemistry, May 2000, American Society for Biochemistry & Molecular Biology (ASBMB)

    Professor Albert Pares

  227. Long-term effects of ursodeoxycholic acid in primary biliary cirrhosis: results of a double-blind controlled multicentric trial

    Article • Journal of Hepatology, April 2000, Elsevier

    Professor Albert Pares

  228. Cholangiocarcinoma in primary sclerosing cholangitis: K-ras mutations and Tp53 dysfunction are implicated in the neoplastic development

    Article • Journal of Hepatology, March 2000, Elsevier

    Professor Albert Pares

  229. Prevalencia y factores asociados a la presencia de esteatosis hepática en varones adultos aparentemente sanos

    Article • Medicina Clínica, January 2000, Elsevier

    Professor Albert Pares

  230. Age, obesity and hyperglycemia but not ethanol intake are the main risk factors for developing fatty liver in men

    Article • Journal of Hepatology, January 2000, Elsevier

    Professor Albert Pares

  231. Natural history of primary sclerosing cholangitis. A longterm follow-up study of 394 european primary sclerosing cholangitis patients

    Article • Journal of Hepatology, January 2000, Elsevier

    Professor Albert Pares

  232. New time dependent prognostic models for Primary Sclerosing Cholangitis (PSC)

    Article • Journal of Hepatology, January 2000, Elsevier

    Professor Albert Pares

  233. Time dependent neural network prognostic model for Primary Sclerosing Cholangitis (PSC)

    Article • Journal of Hepatology, January 2000, Elsevier

    Professor Albert Pares

  234. Differential role of ethanol and acetaldehyde in the induction of oxidative stress in HEP G2 cells: Effect on transcription factors AP-1 and NF-κB

    Article • Hepatology, December 1999, Wolters Kluwer Health

    Professor Albert Pares

  235. Hepatic Fibrogenic Activity in Chronic Alcoholic Pancreatitis

    Article • Pancreas, October 1999, Wolters Kluwer Health

    Professor Albert Pares

  236. S-Adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo-controlled, double-blind, multicenter clinical trial

    Article • Journal of Hepatology, June 1999, Elsevier

    Professor Albert Pares

  237. HLA class II haplotypes in primary sclerosing cholangitis patients from five European populations

    Article • Tissue Antigens, May 1999, Wiley

    Professor Albert Pares

  238. High Bilirubin Levels Interfere with Serum Tartrate-Resistant Acid Phosphatase Determination: Relevance as a Marker of Bone Resorption in Jaundiced Patients

    Article • Calcified Tissue International, April 1999, Springer Science + Business Media

    Professor Albert Pares

  239. Synthesis and Degradation of Collagen in Pancreatic Fibrogenesis

    Article • Pancreas, January 1999, Wolters Kluwer Health

    Professor Albert Pares

  240. Effects of silymarin in alcoholic patients with cirrhosis of the liver

    Article • European Journal of Gastroenterology & Hepatology, July 1998, Wolters Kluwer Health

    Professor Albert Pares

  241. Collagen‐Related Markers of Bone Turnover Reflect the Severity of Liver Fibrosis in Patients with Primary Biliary Cirrhosis

    Article • Journal of Bone and Mineral Research, April 1998, Oxford University Press (OUP)

    Professor Albert Pares

  242. Effects of silymarin in alcoholic patients with cirrhosis of the liver: results of a controlled, double-blind, randomized and multicenter trial

    Article • Journal of Hepatology, April 1998, Elsevier

    Professor Albert Pares

  243. Metadoxine accelerates fatty liver recovery in alcoholic patients: results of a randomized double-blind, placebo-control trial

    Article • Journal of Hepatology, January 1998, Elsevier

    Professor Albert Pares, Prof. Luis Rodrigo

  244. Management of primary biliary cirrhosis: osteoporosis

    Article • January 1998, Springer Science + Business Media

    Professor Albert Pares

  245. Circulating metalloproteinases and their tissue inhibitors in alcoholic liver disease. Relationship to liver fibrosis

    Article • Journal of Hepatology, January 1998, Elsevier

    Professor Albert Pares

  246. Hepatitis G virus infection in chronic liver disease

    Article • Gut, January 1998, BMJ

    Professor Albert Pares

  247. Serum markers of fibrogenesis and collagenolysis in patients with chronic liver disease

    Article • Journal of Hepatology, January 1998, Elsevier

    Professor Albert Pares

  248. The role of metalloproteinases in CCl4 induced fibrosis. Influence of zinc administration

    Article • Journal of Hepatology, January 1998, Elsevier

    Professor Albert Pares

  249. Vitamin D receptor gene polymorphism and bone mass in primary biliary cirrhosis

    Article • Journal of Hepatology, January 1998, Elsevier

    Professor Albert Pares

  250. Zinc Administration Improves Gastric Alcohol Dehydrogenase Activity and First‐Pass Metabolism of Ethanol in Alcohol‐Fed Rats

    Article • Alcoholism Clinical and Experimental Research, December 1997, Wiley

    Professor Albert Pares

  251. Carbohydrate‐Deficient Transferrin as a Marker of Alcohol Consumption in Male Patients with Liver Disease

    Article • Alcoholism Clinical and Experimental Research, August 1997, Wiley

    Professor Albert Pares

  252. Antibodies to mycobacterial 65‐kD heat shock protein cross‐react with the main mitochondrial antigens in patients with primary biliary cirrhosis

    Article • European Journal of Clinical Investigation, August 1997, Wiley

    Professor Albert Pares

  253. Etidronate versus fluoride for treatment of osteopenia in primary biliary cirrhosis: Preliminary results after 2 years

    Article • Gastroenterology, July 1997, Elsevier

    Professor Albert Pares

  254. Serum hyaluronate reflects hepatic fibrogenesis in alcoholic liver disease and is useful as a marker of fibrosis

    Article • Hepatology, December 1996, Wiley

    Professor Albert Pares

  255. FRAXA premutation associated with premature ovarian failure

    Article • American Journal of Medical Genetics, August 1996, Wiley

    Professor Albert Pares

  256. Effects of S-adenosylmethionine on lipid peroxidation and liver fibrogenesis in carbon tetrachloride-induced cirrhosis

    Article • Journal of Hepatology, August 1996, Elsevier

    Professor Albert Pares, Dr María Ángeles Pajares

  257. Effects of ethanol feeding and malnutrition on collagen synthesizing and degrading enzymes in rat pancreas

    Article • Alcohol, May 1996, Elsevier

    Professor Albert Pares

  258. Serum Amino-Terminal Propeptide of Type III Procollagen Levels in Chronic Pancreatitis

    Article • Pancreas, March 1996, Wolters Kluwer Health

    Professor Albert Pares

  259. Effects of prolonged ethanol intake and malnutrition on rat pancreas.

    Article • Gut, February 1996, BMJ

    Professor Albert Pares

  260. Mycobacteria - related to the aetiopathogenesis of primary biliary cirrhosis?

    Article • Journal of Hepatology, January 1996, Elsevier

    Professor Albert Pares

  261. Vertebral fractures and osteopenia in chronic alcoholic patients

    Article • Calcified Tissue International, August 1995, Springer Science + Business Media

    Professor Albert Pares

  262. Bone mass improves in alcoholics after 2 years of abstinence

    Article • Journal of Bone and Mineral Research, October 1994, Oxford University Press (OUP)

    Professor Albert Pares

  263. Protective effect of S-adenosyl-L-methionine (SAMe) in the development of CCl4-induced cirrhosis

    Article • Hepatology, April 1994, Elsevier

    Professor Albert Pares

  264. Role of Zinc in the Process of Pancreatic Fibrosis in Chronic Alcoholic Pancreatitis

    Article • Pancreas, March 1994, Wolters Kluwer Health

    Professor Albert Pares

  265. Acetaldehyde activates the promoter of the mouse α2(I) collagen gene

    Article • Hepatology, February 1994, Wolters Kluwer Health

    Professor Albert Pares

  266. Acetaldehyde activates the promoter of the mouse $alpha;2(I) collagen gene*1

    Article • Hepatology, February 1994, Elsevier

    Professor Albert Pares

  267. Fibrogenic and collagenolytic activity in carbon-tetrachloride-injured rats: beneficial effects of zinc administration

    Article • Journal of Hepatology, January 1994, Elsevier

    Professor Albert Pares

  268. Epidemiology of primary sclerosing cholangitis in Spain

    Article • Journal of Hepatology, January 1994, Elsevier

    Professor Albert Pares

  269. Cyclosporin A increases the biochemical markers of bone remodeling in primary biliary cirrhosis

    Article • Journal of Hepatology, January 1994, Elsevier

    Professor Albert Pares

  270. Disulfiram-induced hepatitis. Report of four cases and review of the literature

    Article • Journal of Hepatology, January 1994, Elsevier

    Professor Albert Pares

  271. An unexpected transformation by reaction of congested α-(o-nitrophenyl) ketones with tris (dimethylamino) methane. A new heterocyclic system: 6,1

    Article • Tetrahedron, January 1994, Elsevier

    Professor Albert Pares

  272. Carbohydrate-deficient transferrin (CDT) as a marker of alcohol consumption in patients with liver disease

    Article • Journal of Hepatology, January 1994, Elsevier

    Professor Albert Pares

  273. Collagen-related markers of bone turnover reflect liver collagen metabolism in primary biliary cirrhosis

    Article • Journal of Hepatology, January 1994, Elsevier

    Professor Albert Pares

  274. Cross-reactivity of anti-Mycobacterium gordonae antibodies with the major mitochondrial autoantigens in primary biliary cirrhosis

    Article • Journal of Hepatology, January 1994, Elsevier

    Professor Albert Pares

  275. Mycobacterium gordonae DNA in liver tissue of patients with primary biliary cirrhosis

    Article • Journal of Hepatology, January 1994, Elsevier

    Professor Albert Pares

  276. Pentoxifylline prevents liver fibrosis but induces cellular damage in carbon tetrachloride injured rats

    Article • Journal of Hepatology, January 1994, Elsevier

    Professor Albert Pares

  277. Prognostic value of the aminopyrine breath test and abstinence in severe alcoholic liver disease

    Article • Journal of Hepatology, January 1994, Elsevier

    Professor Albert Pares

  278. Activation of the mouse $alpha;2(I) collagen gene promoter by acetaldehyde

    Article • Hepatology, October 1993, Elsevier

    Professor Albert Pares

  279. Prediction of alcohol-related casualties in the emergency room: a U.S.-Spain comparison.

    Article • Journal of Studies on Alcohol, May 1993, Alcohol Research Documentation, Inc.

    Professor Albert Pares

  280. Determinants of Ethanol and Acetaldehyde Metabolism in Chronic Alcoholics

    Article • Alcoholism Clinical and Experimental Research, February 1993, Wiley

    Professor Albert Pares

  281. Drinking in the Injury Event: A Comparison of Emergency Room Populations in the United States, Mexico, and Spain

    Article • International Journal of the Addictions, January 1993, Taylor & Francis

    Professor Albert Pares

  282. Relationship between hepatic lipid peroxidation and fibrogenesis in carbon tetrachloride-treated rats: effect of zinc administration

    Article • Clinical Science, December 1992, Portland Press Ltd.

    Ms Maria Teresa Bargalló Escrivà, Professor Albert Pares

  283. S –Adenosylmethionine Treatment Prevents Carbon Tetrachloride—Induced S –Adenosylmethionine Synthetase Inactivation and Attenuates Liver Injury

    Article • Hepatology, October 1992, Wolters Kluwer Health

    Professor Albert Pares, Dr María Ángeles Pajares

  284. Influence of Dietary Zinc on Hepatic Collagen and Prolyl Hydroxylase Activity in Alcoholic Rats

    Article • Hepatology, September 1992, Wolters Kluwer Health

    Professor Albert Pares

  285. Sodium fluoride prevents bone loss in primary biliary cirrhosis

    Article • Journal of Hepatology, July 1992, Elsevier

    Professor Albert Pares

  286. Effects of long-term rifampicin administration in primary biliary cirrhosis

    Article • Gastroenterology, June 1992, Elsevier

    Professor Albert Pares

  287. Validity of self-reported alcohol consumption in the emergency room: data from the United States, Mexico and Spain.

    Article • Journal of Studies on Alcohol, May 1992, Alcohol Research Documentation, Inc.

    Professor Albert Pares

  288. Primary Biliary Cirrhosis and Sclerosing Cholangitis

    Article • January 1992, Springer Science + Business Media

    Professor Albert Pares

  289. Are hepatitis C virus antibodies involved in chronic liver diseases other than non-A, non-B hepatitis?

    Article • Hepatology, December 1991, Wolters Kluwer Health

    Professor Albert Pares

  290. Effect of parenteral amino acid supplementation on short-term and long-term outcomes in severe alcoholic hepatitis: A randomized controlled trial

    Article • Hepatology, December 1991, Wolters Kluwer Health

    Professor Albert Pares

  291. Reply

    Article • Hepatology, December 1991, Elsevier

    Professor Albert Pares

  292. Drinking patterns and problems: a comparison of emergency room populations in the United States and Spain

    Article • Drug and Alcohol Dependence, December 1991, Elsevier

    Professor Albert Pares

  293. Quantitative measurement of fibrosis in pancreatic tissue

    Article • International Journal of Pancreatology, September 1991, Springer Science + Business Media

    Professor Albert Pares

  294. Anemia in primary biliary cirrhosis (PBC). A new prognostic feature

    Article • Journal of Hepatology, January 1991, Elsevier

    Professor Albert Pares

  295. A simple method for assessing timing of liver transplantation in primary biliary cirrhosis (PBC)

    Article • Journal of Hepatology, January 1991, Elsevier

    Professor Albert Pares

  296. A prognestic index (PI) for patient selection and timing of liver transplantation in cirrhosis with ascites

    Article • Journal of Hepatology, January 1991, Elsevier

    Professor Albert Pares

  297. Effects of S-adenosylmethicnine on liver fibrosis in rats

    Article • Journal of Hepatology, January 1991, Elsevier

    Professor Albert Pares

  298. Protective effect of zinc on hepatic lipid peroxidation and fibrogenesis in CCL4-treated rats. A possible role for metallothioneins

    Article • Journal of Hepatology, January 1991, Elsevier

    Professor Albert Pares

  299. Hepatitis C virus antibodies in chronic alcoholic patients: Association with severity of liver injury

    Article • Hepatology, December 1990, Wolters Kluwer Health

    Professor Albert Pares

  300. Hepatitis C Virus Infection in Patients with Nonalcoholic Chronic Liver Disease

    Article • Annals of Internal Medicine, June 1990, American College of Physicians

    Professor Albert Pares

  301. Effects of zinc on hepatic lipid peroxidation and liver fibrosis in carbon tetrachloride-treated rats

    Article • Journal of Hepatology, January 1990, Elsevier

    Professor Albert Pares

  302. Influence of dietary zinc on hepatic collagen and prolyl-hydroxylase activity in alcoholic rats

    Article • Journal of Hepatology, January 1990, Elsevier

    Professor Albert Pares

  303. Rifampicin versus phenobarbital for treatment of pruritus in primary biliary cirrhosis. Results of a crossover randomized trial

    Article • Journal of Hepatology, January 1990, Elsevier

    Professor Albert Pares

  304. Influence of liver disease on hepatic alcohol and aldehyde dehydrogenases

    Article • Gastroenterology, September 1989, Elsevier

    Professor Albert Pares

  305. Liver diseases associated with autoantibodies directed to nuclear envelope components

    Article • Hepatology, June 1989, Wolters Kluwer Health

    Professor Albert Pares

  306. Alcoholic foamy degeneration in Spain. Prevalence and clinico‐pathological features

    Article • Liver International, April 1989, Wiley

    Professor Albert Pares

  307. COMPARISON OF RIFAMPICIN WITH PHENOBARBITONE FOR TREATMENT OF PRURITUS IN BILIARY CIRRHOSIS

    Article • The Lancet, March 1989, Elsevier

    Professor Albert Pares

  308. Association between the histocompatibility antigens and the severity of alcoholic liver disease

    Article • Journal of Hepatology, January 1989, Elsevier

    Professor Albert Pares

  309. Effects of zinc administration on liver fibrogenesis and collagenolysis in rats induced to cirrhosis

    Article • Journal of Hepatology, January 1989, Elsevier

    Professor Albert Pares

  310. Effects of long-term rifampicin administration in primary biliary cirrhosis

    Article • Journal of Hepatology, January 1989, Elsevier

    Professor Albert Pares

  311. Fibrogenesis and collagenolysis in rats induced to liver cirrhosis

    Article • Journal of Hepatology, January 1989, Elsevier

    Professor Albert Pares

  312. Influence of abstinence on serum procollagen type III peptide levels in alcoholic liver disease

    Article • Journal of Hepatology, January 1989, Elsevier

    Professor Albert Pares

  313. Low bone mineral density in primary biliary cirrhosis. Influence of intestinal calcium absorption and bone formation

    Article • Journal of Hepatology, January 1989, Elsevier

    Professor Albert Pares

  314. Comparative study of aminoglycoside nephrotoxicity in normal rats and rats with experimental cirrhosis

    Article • Hepatology, July 1988, Wolters Kluwer Health

    Professor Albert Pares

  315. Autoantibodies against nuclear envelope-associated proteins in primary biliary cirrhosis

    Article • Hepatology, July 1988, Wolters Kluwer Health

    Professor Albert Pares

  316. Esophageal dysfunction in primary biliary cirrhosis

    Article • Journal of Hepatology, January 1988, Elsevier

    Professor Albert Pares

  317. Analysis of factors predicting early seroconversion to anti-HBe in HBeAg-positive chronic hepatitis B

    Article • Journal of Hepatology, January 1988, Elsevier

    Professor Albert Pares

  318. Effects of zinc on liver fibrosis and vitamin a metabolism in rats

    Article • Journal of Hepatology, January 1988, Elsevier

    Professor Albert Pares

  319. URINE ETHANOL ASSESSMENT: A HELPFUL METHOD FOR CONTROLLING ABSTINENCE IN ALCOHOLIC LIVER DISEASE

    Article • Alcohol and Alcoholism, January 1988, Oxford University Press (OUP)

    Professor Albert Pares

  320. Cyanamide hepatotoxicity. Incidence and clinicopathological features

    Article • Liver International, August 1987, Wiley

    Professor Albert Pares

  321. Portal hypertension in primary biliary cirrhosis

    Article • Journal of Hepatology, January 1987, Elsevier

    Professor Albert Pares

  322. Factors influencing blood acetaldehyde levels after ethanol administration in chronic alcoholics

    Article • Journal of Hepatology, January 1987, Elsevier

    Professor Albert Pares

  323. Influence of dietary factors in the development of alcoholic hepatitis

    Article • Journal of Hepatology, January 1987, Elsevier

    Professor Albert Pares

  324. Predictive value of histological features in the progression of alcoholic fatty liver

    Article • Journal of Hepatology, January 1987, Elsevier

    Professor Albert Pares

  325. Serum procollagen type III peptide as a marker of hepatic fibrogenesis in alcoholic hepatitis

    Article • Gastroenterology, May 1986, Elsevier

    Professor Albert Pares

  326. Histological course of alcoholic hepatitis

    Article • Journal of Hepatology, January 1986, Elsevier

    Professor Albert Pares

  327. Esophageal motility disturbances in primary biliary cirrhosis

    Article • Journal of Hepatology, January 1986, Elsevier

    Professor Albert Pares

  328. Nuclear lamina antibodies in primary biliary cirrhosis

    Article • Journal of Hepatology, January 1986, Elsevier

    Professor Albert Pares

  329. Measurement of Fibrosis in Needle Liver Biopsies: Evaluation of A Colorimetric Method

    Article • Hepatology, September 1985, Wolters Kluwer Health

    Professor Albert Pares

  330. Lymphocytotoxic antibodies in primary biliary cirrhosis

    Article • Digestive Diseases and Sciences, September 1985, Springer Science + Business Media

    Professor Albert Pares

  331. Effects of alcoholism and liver injury on hepatic alcohol and acetaldehyde metabolizing enzymes

    Article • Journal of Hepatology, January 1985, Elsevier

    Professor Albert Pares

  332. Evaluation of a quantitative simple method for measuring fibrosis in human liver biopsies

    Article • Journal of Hepatology, January 1985, Elsevier

    Professor Albert Pares

  333. Influence of liver function and alcohol dehydrogenase activity on ethanol metabolism in chronic alcoholics

    Article • Journal of Hepatology, January 1985, Elsevier

    Professor Albert Pares

  334. Relationship between hepatic collagen and portal pressure in alcoholic liver disease

    Article • Journal of Hepatology, January 1985, Elsevier

    Professor Albert Pares

  335. Serum procollagen type III peptide does not reflect hepatic collagen content in alcoholics with inactive cirrhosis

    Article • Journal of Hepatology, January 1985, Elsevier

    Professor Albert Pares

  336. Synoptic Effects on the Local Winds in Todos Santos Bay: A Case Study

    Article • Monthly Weather Review, July 1983, American Meteorological Society

    Professor Albert Pares

  337. Acute Thallium Poisoning: An Evaluation of Different Forms of Treatment

    Article • Journal of Toxicology Clinical Toxicology, January 1982, Taylor & Francis

    Professor Albert Pares

  338. Pulmonary involvement in primary biliary cirrhosis.

    Article • Thorax, March 1981, BMJ

    Professor Albert Pares

  339. Nonoliguric acute renal failure in an intensive care unit

    Article • Intensive Care Medicine, December 1980, Springer Science + Business Media

    Professor Albert Pares

  340. Primary Biliary Cirrhosis Associated with HLA—DRw3

    Article • Tissue Antigens, November 1979, Wiley

    Professor Albert Pares

  341. Primary Sclerosing Cholangitis

    Article • Southern Medical Journal, July 1978, Southern Medical Association

    Professor Albert Pares

  342. Financial Goals and Debt Ratio Determinants: A Survey of Practice in Five Countries

    Article • Financial Management, January 1975, Wiley

    Professor Albert Pares

  343. Mariology

    Article • De Gruyter

    Professor Albert Pares

  344. Renal Tubular Function in Chronic Cholestasis

    Article • Karger Publishers

    Professor Albert Pares